Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Part D Rebate Prospects Advancing In Debt Talks? PhRMA Ratchets Up Opposition

This article was originally published in The Pink Sheet Daily

Executive Summary

Threat of mandatory rebates is "real," CEO Castellani says.

You may also be interested in...



Part D Rebates Would Contribute More Than Half Of Medicare Savings In White House Plan

Plan seeks to cut Medicare costs by a total of $248 billion over 10 years, with mandatory rebates in Part D contributing $135 billion.

Part D Rebates Would Contribute More Than Half Of Medicare Savings In White House Plan

Plan seeks to cut Medicare costs by a total of $248 billion over 10 years, with mandatory rebates in Part D contributing $135 billion.

Debt Proposals Put Off Medicare Cuts To Joint Congressional Committee

Both House Speaker John Boehner and Senate Majority Leader Harry Reid introduced debt ceiling bills that would likely leave potential Medicare/Medicaid Rx reductions to a newly created bipartisan 12-member panel.

Related Content

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel